AI assistant
LISATA THERAPEUTICS, INC. — Director's Dealing 2012
May 11, 2012
34931_dirs_2012-05-11_6a89f6df-bcf1-4a48-aa43-f489b3c83626.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2012-05-11
Reporting Person: GREENACRE MARTYN D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-05-11 | Common stock, $0.001 par value | P | 250000 | — | Acquired | 370000 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-05-11 | Warrant (Right to Buy) | $0.51 | P | 250000 | Acquired | 2017-05-10 | Common stock, par value $0.001 per share (250000) | Indirect |
Footnotes
F1: Purchased by the Reporting Person's IRA in connection with a private placement of the Issuer's securities. Pursuant to the terms of this private placement, NeoStem, Inc., (the "Company") sold units (the "Units") at a per Unit price of $0.40, with each Unit consisting of (a) one share of the Company's common stock, $0.001 par value and (b) one warrant for the purchase of one share of common stock at an exercise price of $0.51 per share, subject to adjustment, expiring five years from the date of issuance and exercisable after a period of six months.